Therapy of Graves’ ophthalmopathy: a novel application of somatostatin analogues

REFERENCES

• BAHN RS, HEUFELDER AE: Pathogenesis of Graves' ophthalmopathy. N ErigL J. Med. (1993) 329:1468–1475.
   PubMed Web of Science ®Google Scholar
• BURCH HB, WARTOFSKY L: Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr. Rev (1993) 14:747–793.
   PubMed Web of Science ®Google Scholar
• HEUFELDER AE: Retro-orbital autoimmunity. BaiIlièir Clin. Endocrinol Metab. (1997) 11:499–520.
   PubMedGoogle Scholar
• HEUFELDER AE: Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur. j Endocrinol. (1995) 132:532–541.
   PubMed Web of Science ®Google Scholar
• WEETMAN AP: Thyroid-associated eyedisease: pathophysiology. Lancet (1991) 338:25–28.
   PubMed Web of Science ®Google Scholar
• WIERSINGA WM, PRUMMEL MF: Pathogenesis of Graves' ophthalmopathy-current understanding. I Clin. Endocrinol. Metab. (2001) 86:501–503.
   PubMed Web of Science ®Google Scholar
• ANISZEWSKI JP, VALYASEVI RW, BAHN RS: Relationship between disease duration and predominant orbital T-cell subset in Graves' ophthalmopathy. I Clin. Endocrinol. Metab. (2000) 85:776–780.
   PubMed Web of Science ®Google Scholar
• PAPPA A, LAWSON JMM, CALDER V, FELLS P, LIGHTMAN S: T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br. I. Ophthalmol (2000) 84:517–522.
   PubMed Web of Science ®Google Scholar
• GRUBECK-LOEBENSTEIN B, TRIEB K, SZTANKAY A, HOLTER W, ANDERL H, WICK G: Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. Clin. Invest. (1994) 3:2738–2743.
   Google Scholar
• FORSTER G, OTTO E, HANSEN C, OCHS K, KAHALY G: Analysis of orbital T cells in thyroid-associated ophthalmopathy. Clin. Exp. Immunol. (1998) 112:427–434.
   PubMed Web of Science ®Google Scholar
• HANSEN C, ROUHI R, FORSTER G, KAHALY GJ: Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. j Clin. Endocrinol. Metab. (1999) 84:1409–1413.
   PubMed Web of Science ®Google Scholar
• BARTALENA L, PINCHERA A, MARCOCCI C: Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev (2000) 21:168–199.
   PubMed Web of Science ®Google Scholar
• WEETMAN AP: Graves' disease. N ErigL J. Med. (2000) 343:1236–1248.
   PubMed Web of Science ®Google Scholar
• PRUMMEL MF: Graves' ophthalmopathy: diagnosis and management. Eur. j NucL Med. (2000) 27:373–376.
   PubMedGoogle Scholar
• LAMBERTS SWJ, VAN DER LELY AJ, DE HERDER WW, HOFLAND LJ: Octreotide. N ErigL 1. Med. (1996) 334:246–254.
   Google Scholar
• DIEZ JJ, IGLESIAS P: Current management of acromegaly. Exp. Opin. Pharmacother. (2000) 1(5):991–1006.
   PubMedGoogle Scholar
• HANSSON HA, PETRUSON B, SKOTTNERM A: Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet (1986) 1:218–219.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE, DUMAS A, PONTIKIDES N, KALTSAS T: Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin. Endocrinol. (Ox!) (1995) 42:571–580.
   PubMed Web of Science ®Google Scholar
• POSTEMA PTE, KWEKKEBOON DJ, VAN HAGEN PM, KRENNING EP: Somatostatin-receptor scintigraphy in Graves' orbitopathy. Eur. j NucL Med. (1996) 23:615–617.
   PubMedGoogle Scholar
• PASQUALI D, SINISI AA, VASSALLO E VENTRE I, BONAVOLONTA G, BELLASTELLA A: Somatostatin receptor expression and effects of octreotide in cultured retroorbital cells from patients with Graves ophthalmopathy. I Endocrinol. Invest. (1997) 20(7 Suppl.):98. Abstract.
   Google Scholar
• PASQUALI D, VASSALLO E ESPOSITO D, BONAVOLONTA G, BELLASTELLA A, SINISI AA: Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. MoL Endocrinol. (2000) 25:63–71.
   Google Scholar
• POSTEMA PTE, KRENNING EP, WIJNGAARDE R et al.: [111In_DTPA-D-Phe1l-octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activityU. Cliii. Endocrinol. Metab. (1994) 79:1845–1851.
   PubMed Web of Science ®Google Scholar
• MONCAYO R, BALDISSERA I, DECRISTOFORO C, KENDLER D, DONNEMILLER E: Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 1111n-octreotide. Thyroid (1997) 7:21–29.
   PubMed Web of Science ®Google Scholar
• GERDING MN, VAN DER ZANT FM, VAN ROYEN EA et al.: Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Endocrinol. (Ox!) (1999) 50:373–379.
   Google Scholar
• KRASSAS GE, KAHALY GJ: The role of octreoscan in thyroid eye disease. Eur. I Endocrinol. (1999) 140:373–375.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE, DOUMAS A, KALTSAS T, HALKIAS A, PONTIKIDES N: Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid (1999) 9:47–52.
   PubMed Web of Science ®Google Scholar
• COLAO A, LASTORIA S, FERRONE D et al.: Orbital scintigraphy with VIn-Diethylenetriamine pentaacetic acid-D-Phell-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. j Clin. Endocrinol. Metab. (1998) 83:3790–3794.
   PubMed Web of Science ®Google Scholar
• COLAO A, PIVONELLO R, LASTORIA S, FAGGIANO A, FERRONE D, LOMBARDI G, FENZI G: Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves's disease. Eur. I Eric/mina (2000) 143:S35–S42.
   Google Scholar
• TRBOJEVIC B, NESOVIC M, CIRIC J et al.: The treatment of Graves' ophthalmopathy with synthetic somatostatin analogue (octreotide). I Endocrinol. Invest. (1991) 14 (Suppl. 4):155. Abstract.
   Google Scholar
• CHANG TC, KAO SCS, HUANG KM: Octreotide and Graves' ophthalmopathy and pretibial myxoedema. Br Med. I (1992) 303:158.
   Google Scholar
• CHANG TC, YAO WC, CHANG CC: Octreotide and urinary glycosaminoglycan in Graves' disease. Br. Med. 1 (1992) 304:1444.
   PubMedGoogle Scholar
• KHOO DHC, TAN YT, FOK ACK, TAN CE: Octreotide in the management of Graves' ophthalmopathy - changes in insulin-like growth factor 1 levels do not predict clinical response. Am. I Clin. Res. (1995) 4:33–42.
   Google Scholar
• DURAK I, DURAK H, ERGIN M, YUREKLI Y, KAYNAK S: Somatostatin receptors in the orbits. Clin. NucL Med. (1995) 20:237–242.
   PubMed Web of Science ®Google Scholar
• OZATA M, BOLU E, SENGUL A et al.: Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels. Thyroid (1996) 6:283–288.
   PubMed Web of Science ®Google Scholar
• KUNG AWC, MICHON J, TM KS, CHAN FL: The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid (1996) 6:381–384.
   PubMed Web of Science ®Google Scholar
• NESOVIC M, TRBOJEVIC B, CIRIC J et al.: Therapy with octreotide in patients with Graves orbitopathy who failed to respond to corticosteroid therapy. I Endocrinol. (1996) 148\(Suppl. 1):P247. Abstract.
   Google Scholar
• UYSAL AR, CORAPCIOGLU D, TONYUKUK VC et al.: Effect of octreotide treatment on Graves' ophthalmopathy. Endocr. j (1999) 46:573–577.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE, KALTSAS T, DUMAS A, PONTIKIDES N, TOLIS G: Lanreotide in the treatment of patients with thyroid eye disease. Eur. j Endocnhol. (1997) 136:416–422.
   PubMed Web of Science ®Google Scholar
• CORSELLO SM, MUSOLINO MTA, DELLA CASA S et al.: Long-acting somatostatin analogues are effective in the treatment of Graves' ophthalmopathy. &mg. Oncol (1998) 67:284. Abstract.
   Google Scholar
• PATEL YC: Molecular pharmacology of somatostatin receptor subtypes. Endocrinol. Invest. (1997) 20:348–367.
   PubMed Web of Science ®Google Scholar
• KRASSAS GE: Somatostatin analogues in the treatment of thyroid eye disease. Thyroid (1998) 8:443–445.
   PubMed Web of Science ®Google Scholar
• MALEC P, ZEMAN K, MARKIEWICZ K, TCHORZEWSKI H, NOWAK Z, BAJ Z: Short term somatostatin infusion affects T-lymphocyte responsiveness in humans. Immunopharmacology (1989) 17:45–49.
   PubMed Web of Science ®Google Scholar